leisure time -WSS

leisure time

author：knowledge 2025-10-01 22:58:16 - browse：542

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Merck, Daiichi strike cancer drug pact worth up to $22 billion

focus

WSS

STAT Readout: Friday, Oct. 20 biotech updates

UnitedHealth, Optum discontinue NaviHealth name

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

STAT Readout: Friday, Oct. 20 biotech updates

Cytokinetics CEO stresses company can launch heart drug on its own

Why a market frenzy over new weight loss drugs defies logic

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Walensky prepares to leave CDC — and Congress — behind

Readout LOUD podcast: Live from the 2023 STAT Summit

The cancer drug shortage isn’t new — and neither are the solutions

Anxious about a speech? A startup wants you to pop a minty cardiac drug

The high cost of giving birth even with insurance

UnitedHealth, Optum discontinue NaviHealth name

Cancer drug shortages should be causing more outrage

Study on Amgen’s bispecific immunotherapy produces positive data

hotspot

J&J lung cancer data amount to new salvo against AstraZeneca

Helping hospitals and community health centers plan for resilience

Study on Amgen’s bispecific immunotherapy produces positive data

Arc Institute generative AI designs new CRISPR systems

Venture capitalist Bob Kocher on the state of digital health

Big Tobacco's 'harm reduction': Is it for real, or a sham?

hotspot

leisure time

focus

knowledge